Apexigen, Inc.
DelistedCIK 1814140fmd_108GB62T2E5Z8827VV1PDT0P8GManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jul 01, 2020 to Jun 30, 2023, 11 periods
| Line item | FY2021 | FY2022 |
|---|---|---|
| Realized investment gains (losses) | 0 | – |
| Research and development | 22 | 23 |
| Total operating expenses | 29 | 33 |
| Operating income | (29) | (33) |
| Other non-operating income (expense) | 0 | 1 |
| Income tax expense | 0 | 0 |
| Net income | (29) | (32) |